

# BUSINESS NEWS PRESS RELEASE

## CONTACT INFORMATION:

**Invero Pharma LLC**

**Douglas Stefanelli, CEO**

**862-800-7788**

**[dstefanelli@inveropharma.com](mailto:dstefanelli@inveropharma.com)**



## FOR IMMEDIATE RELEASE

### **Invero Pharma acquires assets of Neuroprotexeon**

[Montville, NJ June 29, 2021] – Invero Pharma LLC announces it has acquired the assets and intellectual property of Neuroprotexeon Inc. The assets include the rights to develop and commercialize XENEX® (*xenon gas and device for inhalation*) as a potent neuro-protectant with an exceptional safety profile.

The initial indication for XENEX® is the prevention of neurologic injury in post-cardiac arrest patients. It has already achieved the regulatory “trifecta” of:

1. FDA and EMA Orphan Drug status (providing seven and ten year market exclusivity respectively).
2. FDA Fast-Track status
3. FDA and EMA protocol agreements – FDA Special Protocol agreement (SPA) and EMA equivalent (Scientific Advise Working Party Agreement)

Invero Pharma CEO, Doug Stefanelli comments “XENEX® is a potentially lifesaving treatment for patients suffering a cardiac arrest. Disturbingly, the majority of these patients die after undergoing the current standard of care, which is simply providing oxygen and lowering body temperature to preserve brain tissue. XENEX® has the potential to change these outcomes since previous clinical studies demonstrated a significant reduction in brain damage, and more importantly, the possibility to lower mortality rates.”

[Invero Pharma](#) is headquartered in Montville, New Jersey. The US market alone for Xenex in this indication has been estimated to be \$300 million. Development in additional indications such as stroke may possible.

Invero Pharma is a late clinical-stage pharmaceutical company developing the proprietary use of xenon gas, delivered via a patented inhalation device, to [protect against brain cell death following acute neurologic injury](#). Invero Pharma is currently preparing for a Phase III Clinical Trial in Out of Hospital Cardiac Arrest (OHCA) following a publication of [positive Phase II Clinical Trial results in JAMA, March 2016](#).